CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma

1. Julie & Holleman LLP is investigating Checkpoint's sale to Sun Pharma. 2. Concerns raised over conflicts with Checkpoint's controlling shareholder, Fortress Biotech. 3. Checkpoint recently gained FDA approval for a significant cancer treatment. 4. Shareholders could receive up to $4.80 per share with EU approval. 5. Fortress may benefit disproportionately from royalty payments on cosibelimab.

M&A

80

4m saved

Insight

Article

FAQ

Why Bearish?

The investigation into potential conflicts indicates possible shareholder dilution and dissatisfaction, historically leading to drops in stock price when similar situations arise. Given that Fortress may benefit more than ordinary shareholders, this raises concerns about long-term shareholder value.

How important is it?

The article highlights significant issues regarding shareholder benefits and potential conflicts, which are highly relevant to investor perceptions and stock value. Legal challenges could also delay or derail the proposed sale.

Why Short Term?

Immediate investor sentiment will likely shift due to the investigation, impacting CKPT's stock price in the short term. Similar scenarios in other companies have previously led to quick sell-offs.

Related Companies

FBIO SNY

NEW YORK, March 10, 2025 /PRNewswire/

Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal.

For a free consultation, or to learn more, contact partner W. Scott Holleman, Esq. by email at contact@julieholleman.com or by telephone at (929) 415-1020. You may also visit: https://julieholleman.com/checkpoint-therapeutics-inc/

Checkpoint is a pharmaceutical company focused on developing novel treatments for patients with solid tumor cancers. The company is controlled by its founder, Fortress Biotech.

Checkpoint recently received FDA approval for the use of cosibelimab-ipdl (branded as UNLOXCYT) for the treatment of adults with certain cancers. Checkpoint has not yet received European Union approval for cosibelimab. The U.S. market for cosibelimab is estimated to be worth over $1 billion annually, and the global market could be several times greater.

On March 9, 2023, Checkpoint announced the deal with Sun Pharma, under which shareholders will receive $4.10 per share in cash (or a total of $355 million). If cosibelimab receives EU approval within a prescribed time period, shareholders could also receive up to $0.70 per share through a "contingent value right," or CVR.

Julie & Holleman, a law firm whose attorneys have helped recover hundreds of millions of dollars for shareholders, is concerned about both conflicts and price. In addition to what other shareholders will receive, Fortress Biotech will receive royalty payments related to eventual sales of cosibelimab. Accordingly, while Fortress and Sun Pharma stand to reap enormous benefits from cosibelimab at the expense of ordinary shareholders.

ABOUT THE FIRM

Julie & Holleman is a boutique law firm that focuses on shareholder litigation, including derivative actions, mergers and acquisitions cases, securities fraud class actions, and corporate investigations. The firm's attorneys litigate in state and federal courts across the nation and have helped secure hundreds of millions of dollars for aggrieved companies and their shareholders. For more information about the firm, please visit www.julieholleman.com. This notice may constitute attorney advertising.

CONTACT INFORMATION

Julie & Holleman LLP
W. Scott Holleman, Esq.
157 East 86th Street
4th Floor
New York, NY 10028
(929) 415-1020
www.julieholleman.com

SOURCE Julie & Holleman LLP